Romiplostim for Platelet Engraftment After Haploidentical or Matched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation
NCT07919977, Phase 2, Recruiting, Liping Dou
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Romiplostim for Platelet Engraftment After Haploidentical or Matched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation | ClinicalTrials.gov |
| NCT number | NCT07919977 | ClinicalTrials.gov |
| Status | Recruiting | ClinicalTrials.gov |
| Phases | Phase 2 | ClinicalTrials.gov |
| Enrollment | 120 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Liping Dou | ClinicalTrials.gov |
| Conditions | Hematologic Diseases | ClinicalTrials.gov |
| Interventions | Romiplostim, Best Supportive Care (BSC) | ClinicalTrials.gov |
| First posted | 2026-11-05 | ClinicalTrials.gov |
| Last updated | 2026-11-06 | ClinicalTrials.gov |
Registered outcomes 8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Platelet Engraftment Rate at Day +30 After Allogeneic Hematopoietic Stem Cell Transplantation | Day +30 after allo-HSCT | The proportion of participants who achieve platelet engraftment at day +30 after allo-HSCT will be assessed. Platelet engraftment is defined as a platelet count greater than 20×10⁹/L for 7 consecutive days without platelet transfusion support. | ClinicalTrials.gov |
| Secondary | Time to Platelet Engraftment | From transplantation (Day 0) through Day +60 | Time from allo-HSCT to platelet engraftment. Platelet engraftment is defined as a platelet count \>20 × 10⁹/L for seven consecutive days without platelet transfusion support. | ClinicalTrials.gov |
| Secondary | Time to Neutrophil Engraftment | From transplantation (Day 0) through Day +60 | Time from allogeneic hematopoietic stem cell transplantation to neutrophil engraftment. | ClinicalTrials.gov |
| Secondary | Relapse Rate | From transplantation (Day 0) through 1 year | The proportion of participants who experience relapse of their underlying hematologic disease after transplantation during the observation period. | ClinicalTrials.gov |
| Secondary | Graft-versus-Host Disease (GVHD） | From transplantation (Day 0) through Day 2 years | The proportion of participants who develop graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation during the observation period. | ClinicalTrials.gov |
| Secondary | Non-Relapse Mortality | From transplantation (Day 0) through 2 years | The proportion of participants who die without prior relapse of their underlying hematologic disease after transplantation during the observation period. | ClinicalTrials.gov |
| Secondary | Overall Survival | From transplantation (Day 0) through 2 years | Overall survival (OS) is defined as the time from the start of study treatment to death from any cause. Participants who are alive at the end of follow-up will be censored at the date they were last known to be alive. Survival status will be assessed by telephone or in-person visits every 2-3 months after completion of study treatment. | ClinicalTrials.gov |
| Secondary | Incidence of Grade 3 or Higher Adverse Events and Laboratory Abnormalities | From transplantation (Day 0) through Day +100 | The number and percentage of participants who experience grade 3 or higher adverse events or laboratory abnormalities during study treatment and at the end-of-treatment visit. Clinically significant laboratory abnormalities will be reassessed until resolution or stabilization. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)